{"id":"W2884466498","doi":"10.1007/s00125-018-4670-7","title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","year":2018,"lang":"en","type":"review","venue":"Diabetologia","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":964,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"University of Glasgow; Novo Nordisk; Valeant Pharmaceuticals International; Sanofi; GlaxoSmithKline; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Empagliflozin; Natriuresis; Afterload; Heart failure; Medicine; Adipokine; Context (archaeology); Diuresis; Diabetes mellitus; Pharmacology; Type 2 diabetes; Internal medicine; Endocrinology; Kidney; Blood pressure; Biology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02485564613699635,"score_gpt":0.2764991405902196,"score_spread":0.2516434944532232,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}